# Effect of Sitafloxacin and Amikacin Liposome Inhalation Suspension on Clarithromycin-Resistant Pulmonary Mycobacterium avium Complex Disease: A Case Series

## TL;DR

This case series explores the effectiveness of sitafloxacin and amikacin liposome inhalation in treating a difficult-to-manage type of lung infection caused by Mycobacterium avium complex.

## Contribution

The study introduces a potential new treatment approach for clarithromycin-resistant MAC disease using inhaled antibiotics.

## Key findings

- Two out of four patients achieved sputum culture negativity after treatment.
- Success was observed in younger patients without cavitary lesions.
- STFX and ALIS may be effective adjuncts to standard therapy for CAM-resistant MAC.

## Abstract

Clarithromycin (CAM)-resistant pulmonary Mycobacterium avium complex (MAC) disease poses significant treatment challenges. This case series describes four patients treated with sitafloxacin (STFX) and amikacin liposome inhalation suspension (ALIS) in addition to standard guideline-based therapy (GBT). Sputum culture negativity was achieved in two patients, both under 65 years old and without cavitary lesions. These findings suggest the potential efficacy of STFX and ALIS as adjuncts to GBT for CAM-resistant pulmonary MAC disease, particularly in younger patients with non-cavitary disease.